NCT00948168

Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

6-Months Exenatide and Glucose Homeostasis Determinants in Type 2 Diabetic Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Academic / Other
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine in type 2 diabetic patients in secondary failure to combined oral therapy whether, besides improvement in glycemic control, addition of exenatide, a new drug introduced to treat diabetes before addition of insulin to current therapy, over 6 months is associated with improvement in beta-cell function, insulin sensitivity following 24-hours discontinuation of the drug.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	exenatide (Byetta)	all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-07-01
• Completion: 2009-07-01
• First posted: 2009-07-29
• Last updated: 2009-07-31

Locations

1 site across 1 country: Belgium